Castle biosciences stock.

Castle Biosciences, Inc. Doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead ...The estimated net worth of Daniel Bradbury is at least $1.27 million as of November 20th, 2023. Mr. Bradbury owns 63,885 shares of Castle Biosciences stock worth more than $1,270,034 as of November 24th. This net worth evaluation does not reflect any other assets that Mr. Bradbury may own. Learn More about Daniel Bradbury's net worth.On average, Wall Street analysts predict. that Castle Biosciences's share price could reach $32.13 by Aug 4, 2024. The average Castle Biosciences stock price prediction forecasts a potential upside of 63.57% from the current CSTL share price of $19.64. Howl’s Moving Castle is a beloved Japanese animated film that has captured the hearts of audiences worldwide since its release in 2004. Based on the novel by Diana Wynne Jones, the film tells the story of a young woman named Sophie who is c...Shares of Castle Biosciences are trading down 1.98% over the last 24 hours, at $13.40 per share. A move to $30.00 would account for a 123.88% increase from the current share price. About Castle ...

thefly.com — Castle Biosciences raises FY23 revenue view to at least $200M, consensus $187.1M News • Nov 1, 2023 GamesIndustry.biz — Remedy posts flat revenue for Q3 2023Nov 24, 2023 · Castle Biosciences Inc CSTL Morningstar Rating Stock XNAS Rating as of Nov 24, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns Financials Valuation Operating...

Jun 5, 2023 · Shares of Castle Biosciences ( CSTL 2.42%) were down more than 47% on Monday afternoon as three analysts lowered their price targets for the medical diagnostic stock. The healthcare stock is down ...

Innovators With A Proven Track Record of Success. An experienced team with deep expertise in discovering, developing, and commercializing diagnostic and prognostic tests. Castle Biosciences offers diagnostic tests that provide actionable, tumor-specific information for improved treatment decisions and patient outcomes.Insiders trading at Castle Biosciences. Over the last 4 years, insiders at Castle Biosciences have traded over $369,408,068 worth of Castle Biosciences stock and bought 782,652 units worth $12,524,690 . The most active insiders traders include Daniel Bradbury, Derek J Maetzold, and Joseph C. Iii Cook.On average, Castle …The bid-ask spread can indicate a stock’s liquidity, which is how easy it is to buy and sell in the marketplace. Often, a smaller spread suggests higher liquidity, meaning more buyers …Castle Biosciences, Inc. (CSTL) Stock Price | Stock Quote Nasdaq - MarketScreener CASTLE BIOSCIENCES, INC. PDF Report Castle Biosciences, Inc. Stock price …Shares of Castle Biosciences ( CSTL 0.15%) closed this week down 12.6% for the week, after being down as much as 18.3% for the week, according to data provided by S&P Global Market Intelligence ...

Following this news, Relmada’s stock price fell nearly 80% to close at $6.48 per share on October 13, 2022. ... Castle Biosciences, Inc. (NASDAQ: CSTL)

Kim Caple CSTL stock SEC Form 4 insiders trading. Kim has made over 3 trades of the Castle Biosciences stock since 2022, according to the Form 4 filled with the SEC. Most recently Kim exercised 440 units of CSTL stock worth $8,642 on 14 July 2023.. The largest trade Kim's ever made was exercising 3,825 units of Castle Biosciences …

At Castle Biosciences, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of …The latest price target for Castle Biosciences ( NASDAQ: CSTL) was reported by Keybanc on Friday, August 4, 2023. The analyst firm set a price target for …Castle Biosciences Company Info. Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. Overview. Castle Biosciences is improving health through our innovative tests that guide patient care. For the diseases that our portfolio of tests cover, we believe the traditional approach to developing a treatment plan for cancers and other diseases using clinical and pathology factors alone is inadequate and can be improved by incorporating …Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes.Dec 1, 2023 · Stock analysis for Castle Biosciences Inc (CSTL:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Track Castle Biosciences Inc (CSTL) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors

According to the issued ratings of 4 analysts in the last year, the consensus rating for Castle Biosciences stock is Buy based on the current 4 buy ratings for CSTL. The average twelve-month price prediction for Castle Biosciences is $32.29 with a high price target of $41.00 and a low price target of $25.00. Learn more on CSTL's analyst rating ... Castle Biosciences Inc (CSTL) stock is down -47.58% while the S&P 500 has gained 0.08% as of 10:52 AM on Monday, Jun 5. CSTL is lower by -$10.81 from the previous closing price of $22.73 on volume of 2,678,434 shares. Over the past year the S&P 500 is up 3.99% while CSTL is lower by -44.69%. CSTL lost -$2.71 per share the over the last 12 months.The Castle Biosciences, Inc. stock price gained 1.95% on the last trading day (Wednesday, 29th Nov 2023), rising from $19.48 to $19.86.During the last trading day the stock fluctuated 3.77% from a day low at $19.61 to a day high of $20.35.The price has risen in 7 of the last 10 days and is up by 3.76% over the past 2 weeks. Volume has …Jun 5, 2023 · According to 7 analyst offering 12-month price targets in the last 3 months, Castle Biosciences has an average price target of $35.14 with a high of $41.00 and a low of $25.00. The stock price of Castle Biosciences, a skin cancer diagnostic company, has seen a large 24% drop over the last ten trading days, while it is down 14% over the last five trading days.Castle Biosciences stock gains ~9% after co reports beat-and-raise Q2 SA News Tue, Aug. 09, 2022 1 Comment. Castle Biosciences GAAP EPS of -$0.06 beats by $0.70, revenue of $34.8M beats by $6.43MCSTL Castle Biosciences, Inc. Stock Price & Overview 2.63K followers $19.99 0.13 ( +0.65%) 4:00 PM 11/30/23 NASDAQ | $USD | Post-Market: $19.99 4:17 …

Insiders trading at Castle Biosciences. Over the last 4 years, insiders at Castle Biosciences have traded over $369,408,068 worth of Castle Biosciences stock and bought 782,652 units worth $12,524,690 . The most active insiders traders include Daniel Bradbury, Derek J Maetzold, and Joseph C. Iii Cook.On average, Castle …

Jun 2, 2023 · Shares of Castle Biosciences ( CSTL 0.15%) closed this week down 12.6% for the week, after being down as much as 18.3% for the week, according to data provided by S&P Global Market Intelligence ... The estimated Net Worth of Bernhard E. Spiess is at least $7.14 Million dollars as of 10 December 2021. Mr. Spiess owns over 1,500 units of Castle Biosciences stock worth over $346,275 and over the last 4 years he sold CSTL stock worth over $6,796,778. In addition, he makes $0 as Chief Business Officer at Castle Biosciences.Find real-time CSTL - Castle Biosciences Inc stock quotes, company profile, news and forecasts from CNN Business.Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma ...Castle Biosciences is forecast to grow earnings and revenue by 32.8% and 14.8% per annum respectively. EPS is expected to grow by 32.1% per annum. Return on equity is forecast to be -26.8% in 3 years.Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that data spanning its dermatologic portfolio of gene expression profile (GEP) tests was recently presented at the 2023 American Society for Dermatologic Surgery (ASDS) Annual Meeting in Chicago.David Kabakoff CSTL stock SEC Form 4 insiders trading. David has made over 21 trades of the Castle Biosciences stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 30,000 units of CSTL stock worth $2,252,100 on 17 June 2021.. The largest trade he's ever made was selling 250,000 units of Castle …Key Stock Data P/E Ratio (TTM) N/A EPS (TTM) $-2.84 Market Cap $537.94 M Shares Outstanding 26.91 M Public Float 24.91 M Yield CSTL is not currently paying a regular dividend. Latest Dividend N/A...Castle Biosciences, Inc. (NASDAQ:NASDAQ:CSTL) Q3 2022 Earnings Conference Call November 2, 2022 4:30 PM ETCompany ParticipantsCamilla Zuckero - Vice...

The all-time high Castle Biosciences stock closing price was 97.33 on February 09, 2021. The Castle Biosciences 52-week high stock price is 29.59, which is 64.4% above the current share price. The Castle Biosciences 52-week low stock price is 9.26, which is 48.6% below the current share price. The average Castle Biosciences stock price for the ...

Stocks trading online may seem like a great way to make money, but if you want to walk away with a profit rather than a big loss, you’ll want to take your time and learn the ins and outs of online investing first. This guide should help get...

These 4 analysts have an average price target of $38.75 versus the current price of Castle Biosciences at $22.02, implying upside. Below is a summary of how these 4 analysts rated Castle ...The 31-GEP test (DecisionDx-Melanoma; Castle Biosciences Inc, Friendswood, TX) was used to analyze the expression of 27 prognostic genes (28 probes) and three control genes from primary CM tumors, as previously described. 21 All 31-GEP testing was performed in a College of American Pathologists–accredited and Clinical …Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to …Track Castle Biosciences Inc (CSTL) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsCastle Biosciences stock opened at $19.97 on Monday. The firm has a market capitalization of $537.39 million, a P/E ratio of -7.03 and a beta of 0.97. The company has a 50-day simple moving ...AltheaDx filed for an initial public stock offering in December 2014 but shelved the proposed stock sale in early 2015. Castle Biosciences, which went public in 2019, makes tests that help guide ...The stock price of Castle Biosciences, a skin cancer diagnostic company, has seen a large 24% drop over the last ten trading days, while it is down 14% over the last five trading days. Jul 13, 2023 · Shares of Castle Biosciences ( CSTL -7.22%) were down more than 20.2% for the week as of Thursday's close, according to data provided by S&P Global Market Intelligence. The healthcare stock closed ... Castle Biosciences, Inc. plans to launch a genomic test by the end of 2025 that can guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis, psoriasis, and related conditions. New data shows the test's ability to distinguish between responders and non-responders to an atopic dermatitis therapy, as well as …

Castle Biosciences Inc Stock Price History. Castle Biosciences Inc’s price is currently up 9.67% so far this month. During the month of November, Castle Biosciences Inc’s stock price has reached a high of $19.36 and a low of $15.28. Over the last year, Castle Biosciences Inc has hit prices as high as $29.59 and as low as $9.26. Year to …Stock Info Stock Quote Price $19.88 Volume 52,546 Change +0.03 % Change +0.15% Today's Open $19.69 Previous Close $19.85 Intraday High $20.26 Intraday Low $19.69 52-Week High $29.59 52-Week Low $9.26 Pricing delayed by 20 minutes. Last Updated 11/24/2023 1:00 PM ET Stock Chart View stock chart as data table From: To:The Castle Biosciences, Inc. stock price gained 1.95% on the last trading day (Wednesday, 29th Nov 2023), rising from $19.48 to $19.86.During the last trading day the stock fluctuated 3.77% from a day low at $19.61 to a day high of $20.35.The price has risen in 7 of the last 10 days and is up by 3.76% over the past 2 weeks. Volume has …Mr. Harrison CSTL stock SEC Form 4 insiders trading. Miles has made over 2 trades of the Castle Biosciences stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 3,825 units of CSTL stock worth $76,041 on 2 June 2023.. The largest trade he's ever made was exercising 3,825 units of Castle Biosciences …Instagram:https://instagram. stock beta meaningvt stocksspyi dividenddividend qqq The estimated Net Worth of Mara G. Aspinall is at least $1.28 million dollars as of 2 June 2023. Ms. Aspinall owns over 3,825 units of Castle Biosciences stock worth over $485,681 and over the last 8 years she sold CSTL stock worth over $494,800. In addition, she makes $302,714 as Independent Director at Castle Biosciences. nyse borroracle stoc The stock price of Castle Biosciences, a skin cancer diagnostic company, has seen a large 24% drop over the last ten trading days, while it is down 14% over the last five trading days.Nov 27, 2023 · Castle Biosciences Stock Forecast 11-20-2023. Forecast target price for 11-20-2023: $ 18.23. Negative dynamics for Castle Biosciences shares will prevail with possible volatility of 2.962%. Pessimistic target level: 17.92. Optimistic target level: 18.47. are bonds a good investment now PURPOSE KRAS is the most mutated proto-oncogene that has been identified in cancer, and treatment of patients with KRAS mutations remains an arduous challenge. Recently, KRASG12C mutation has attracted special interest because it is now considered potentially druggable with recently developed covalent small-molecule KRASG12C inhibitors. …Derek has made over 103 trades of the Castle Biosciences stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 600 units of CSTL stock worth 12,060$ on 3 August 2023. 世界市場 道具 ポートフォリオ. Track performance, allocation, dividends, and risks ...2 Ağu 2023 ... Castle Biosciences CSTL · Profile · Stock Chart · Financial Statements · Financial Ratios · Other stocks of industry "Diagnostics research" ...